Archive | case study

HIV Drug Could Re-sensitize Therapy-resistant Melanoma

The expression of the PAX3 and MITF genes in melanoma can cause early, nonmutational, reversible drug resistance. Melanoma tissues that express these genes can then later develop mutational, irreversible drug resistance. The HIV drug nelfinavir can prevent this targeted therapy resistance in melanoma, according to a study published in Cancer Cell.1

Read the full story

Posted in Latest Research, Other Melanoma Research, case study

Lower Vitamin D Levels Linked to Poorer Melanoma Outcomes

Lower vitamin D levels were associated with poorer overall survival, melanoma-specific survival, and disease-free survival independent of a strong association between lower vitamin D and higher C-reactive protein, a study published in the Journal of Clinical Oncology has shown.1

Read the full story

Posted in Latest Research, Health Professionals, Journals,Papers & Reports, Other Melanoma Research, case study

Melanoma Cells’ Transition from Benign to Malignant Mapped, and Reversed, in Yale Lab

The mechanism by which benign melanoma cells change into malignant ones is greatly affected by the cells’ stiffness, as determined by the specific balance of two signaling pathways — which, in turn, can be affected by a genetic deletion, according to Yale University researchers.

Read the full story

Posted in Latest Research, Other Melanoma Research, case study

Lower Vitamin D Levels Predict Poor Survival Outcomes in Melanoma

In patients with melanoma, lower 25-hydroxyvitamin D (vitamin D) levels were associated with poorer survival outcomes, according to a prospective study. This association was independent of C-reactive protein (CRP) levels.

Read the full story

Posted in Latest Research, case study

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories